SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-12-403458
Filing Date
2012-09-25
Accepted
2012-09-25 17:04:58
Documents
5
Effectiveness Date
2012-09-25

Document Format Files

Seq Description Document Type Size
1 PROXY STATEMENT SUPPLEMENT d417909ddefa14a.htm DEFA14A 621877
2 GRAPHIC g417909g35c47.jpg GRAPHIC 5837
3 GRAPHIC g417909g46c13.jpg GRAPHIC 9078
4 GRAPHIC g417909g67p72.jpg GRAPHIC 11651
5 GRAPHIC g417909g88s00.jpg GRAPHIC 10161
  Complete submission text file 0001193125-12-403458.txt   674360
Mailing Address 12270 WILKINS AVENUE ROCKVILLE MD 20852
Business Address 12270 WILKINS AVENUE ROCKVILLE MD 20852 301-770-3099
NABI BIOPHARMACEUTICALS (Filer) CIK: 0000072444 (see all company filings)

IRS No.: 591212264 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-35285 | Film No.: 121109521
SIC: 2836 Biological Products, (No Diagnostic Substances)